Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative therapies work by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these substances boost insulin release and suppress glucagon

The burgeoning landscape of innovative treatments for metabolic management has glp-1 seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting substantial weight loss – they exhibit intriguing contrasts